All In Biotech

Drug Trial Radar · NCT00724984

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma

Last checked: Nov 19, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Jul 2008

Primary completion

Nov 2012

Sponsor

Lead sponsor
Pharmacyclics LLC.AbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.

Conditions

  • Lymphoma
  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin

Interventions

  • PCI-24781Drug

    Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart ("BID"), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease ResponseTime frame: From the Date of PCI-24781 first administration to Cycle 2 Day 1
  2. Phase II: Overall Response Rate (CR+PR)Time frame: From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Northwestern University Medical School

    Chicago, Illinois

  • Horizon Oncology Center

    Lafayette, Indiana

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • University of Vermont and Fletcher Allen Health Care

    Burlington, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.